Yüklüyor......

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program

BACKGROUND: The global EINSTEIN DVT and PE studies compared rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K antagonist therapy and demonstrated non-inferiority for efficacy and superiority for major bleeding. Owing to differences in targeted anticoa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Thromb J
Asıl Yazarlar: Yamada, Norikazu, Hirayama, Atsushi, Maeda, Hideaki, Sakagami, Satoru, Shikata, Hiroo, Prins, Martin H, Lensing, Anthonie WA, Kato, Masaharu, Onuma, Junichi, Miyamoto, Yuki, Iekushi, Kazuma, Kajikawa, Mariko
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2015
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4339301/
https://ncbi.nlm.nih.gov/pubmed/25717286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-015-0035-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!